NVIDIA BioNeMo is a generative AI framework for drug discovery, accelerating biomolecular model development and deployment.
Why it matters
overview
NVIDIA BioNeMo is a generative AI framework tool developed by NVIDIA that enables drug researchers, scientists, and developers to accelerate AI-driven drug discovery and biomolecular model development. It integrates protein language models and OpenFold to facilitate biomolecular prediction and generation processes.
features
NVIDIA BioNeMo provides a comprehensive suite of tools and pre-trained models designed for AI-driven drug discovery and computational biology. The platform leverages NVIDIA's GPU technologies to optimize performance for demanding biomolecular AI workloads.
use cases
NVIDIA BioNeMo is designed for professionals and organizations engaged in advanced biomolecular research and drug development, seeking to leverage AI for accelerated discovery processes.
how to use
NVIDIA BioNeMo functions as a cloud service and framework, enabling researchers to develop and deploy AI applications for biomolecular modeling. Users can access pre-trained models or train custom models on NVIDIA's optimized infrastructure.
pricing
The NVIDIA BioNeMo Framework is free to use, providing access to programming tools, packages, and optimized pre-trained biomolecular models. For production-level workloads and higher performance requirements, NVIDIA offers paid enterprise tiers.
Free Tier
Vendor website advertises a free tier.
Similar Tools
NVIDIA BioNeMo is positioned as a leading platform for AI-driven drug discovery, leveraging NVIDIA's expertise in GPU-accelerated computing. Its comprehensive suite of optimized models and frameworks aims to reduce preclinical development time and cost.
Generate Biomedicines focuses on generative protein design, utilizing AI to create novel protein therapeutics by learning from protein sequences, structures, and biological function.
Similar to NVIDIA BioNeMo in its use of AI for biomolecular generation and prediction, Generate Biomedicines specializes in protein therapeutics and integrates a 'generate-build-measure-learn' loop for experimental feedback. BioNeMo offers a broader toolkit that also includes small molecule generation and a wider array of biomolecular models.
Evo 2 is a genomic foundation model capable of generalist prediction and design tasks across DNA, RNA, and proteins, trained with 40 billion parameters.
Evo 2 is directly comparable to NVIDIA BioNeMo in its foundational model approach for diverse biomolecules. While BioNeMo integrates specific models like OpenFold and ESMFold for protein structure prediction, Evo 2 is presented as a single genomic foundation model for prediction and design across multiple biological sequences.
Insilico Medicine is a pioneer in generative chemistry, leveraging AI to design novel small molecules and accelerate drug discovery, with a focus on advancing drugs into clinical phases.
Insilico Medicine's primary strength lies in generative AI for small molecule design, which is a key component of NVIDIA BioNeMo's broader offering that also includes protein generation and prediction. Insilico Medicine has a notable track record of moving AI-designed drugs into clinical trials.
Aurigene.AI is an AI-powered cloud platform designed to accelerate the entire Design-Make-Test-Analyze (DMTA) cycle for various molecule types, including small molecules, peptides, and biologics.
Aurigene.AI offers a comprehensive, end-to-end AI platform for drug discovery, similar to NVIDIA BioNeMo's broad framework. It supports a wider range of molecule types and integrates across the entire DMTA cycle, whereas BioNeMo emphasizes its suite of biomolecular prediction and generation models.
AI Reputation Report
ChatGPT, Perplexity, Gemini, Claude & Grok answer buyer questions about NVIDIA BioNeMo every day. See whether they name NVIDIA BioNeMo — or send buyers to a rival.
